Q-omics provides the consensus-scored CCDC141 profile across patient tissues and cancer cell-line models. CCDC141 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CCDC141 is differentially expressed in 10, with the highest sampling consensus in LUAD. Additionally, CCDC141 RNA expression shows 22,171 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where CCDC141 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC141 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC141 survival associations across molecular data types. CCDC141 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC141 RNA expression–survival associations across cancer types. High CCDC141 expression shows unfavorable associations in LUSC and KIRP, but favorable associations in KIRC, HNSC, LGG and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for CCDC141 RNA expression.
This table summarizes CCDC141 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CCDC141. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC141 shows lower tumor expression in LUAD, BLCA, THCA, LUSC and COAD and higher tumor expression in KIRC. The LUAD box plot shows higher CCDC141 RNA expression in normal versus tumor tissue (log2 FC = −1.863, t-test p < 0.001).
This table shows molecular features associated with CCDC141 in patient tissues and cancer cell lines. In patient samples, CCDC141 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC141 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
